Early breast cancer

International Journal of Clinical Oncology

Volumn 11, Issue 2, 2006, Pages 108-119

  Suzuki, Tomoyoshi ^a   Toi, Masakazu ^a   Saji, Shigehira ^a   Horiguchi, Kazumi ^a   Aruga, Tomoyuki ^a   Suzuki, Eiji ^a   Horiguchi, Shinichiro ^a   Funata, Nobuaki ^a   Karasawa, Katsuyuki ^a   Kamata, Noriko ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Breast cancer; DCIS; Local control; Multidisciplinary therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; METHOTREXATE; MYC PROTEIN; ORAL CONTRACEPTIVE AGENT; PACLITAXEL; PREDNISOLONE; PROTEIN P53; TAMOXIFEN; TAMOXIFEN CITRATE; TELOMERASE; VINCRISTINE;

ALCOHOL CONSUMPTION; ANTHROPOMETRY; BODY MASS; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; DIAGNOSTIC IMAGING; DIET; DRUG EFFICACY; DRUG INDUCED CANCER; EARLY CANCER; ECHOGRAPHY; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; HORMONE SUBSTITUTION; HUMAN; MAMMOGRAPHY; MENARCHE; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; ORAL CONTRACEPTION; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMBINED MODALITY THERAPY; FEMALE; HUMANS; JAPAN;

EID: 33645875614     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0564-7     Document Type: Review

References (123)

1. T Ikeda F Akiyama M Hiraoka 1998 The current status of the treatment of ductal carcinoma in situ of Japanese women, especially breast conserving operation in relation to the surgical margin and short term outcome Breast Cancer 5 53 58
2. K Takahashi M Saito M Makita 2000 Surgery for ductal carcinoma in situ Breast Cancer 7 337 340
3. Japanese Breast Cancer Society 2002 Japanese classification of breast cancer, 14th edn (in Japanese) Kanahara Syuxtupan Tokyo 13 14
4. H Tsukuma W Ajiki A Oshima 2004 Cancer incidence in Japan (in Japanese) Gan To Kagaku Ryoho 31 840 846
5. Collaborative group on hormonal factors in breast cancer 2001 Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease Lancet 358 1389 1399
6. C Nagata YH Hu H Shimizu 1995 Effects of menstrual and reproductive factors on the risk of breast cancer: meta-analysis of the case-control studies in Japan Jpn J Cancer Res 86 910 915
7. V Beral 2003 Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 419 427
8. Y Minami N Ohuchi A Fukao 1997 Risk factors for breast cancer: a case-control study of screen-detected breast cancer in Miyagi prefecture, Japan Breast Cancer Res Treat 44 225 233
9. Collaborative group on hormonal factors in breast cancer 2002 Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50,302 women with breast cancer and 96,973 women without the disease Lancet 360 187 195
10. Collaborative Group on Hormonal Factors in Breast Cancer 1996 Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer Lancet 347 1713 1727
11. M Melbye J Wohlfahrt JH Olsen 1997 Induced abortion and the risk of breast cancer N Engl J Med 336 81 85
12. JR Palmer LA Wise LL Adams-Campbell 2004 A prospective study of induced abortion and breast cancer in African-American women Cancer Causes Control 15 105 111
13. V Beral D Bull R Doll 2004 Breast cancer and abortion: collaborative reanalysis of date from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries Lancet 363 1007 1016
14. PA van den Brandt D Spiegelman SS Yaun 2000 Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk Am J Epidemiol 152 514 527
15. PH Lahmann K Hoffmann N Allen 2004 Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC) Int J Cancer 111 762 771
16. M Ahlgren M Melbye J Wohlfahrt 2004 Growth patterns and the risk of breast cancer in women N Engl J Med 351 1619 1626
17. H Merzenich H Boeing J Wahrendorf 1993 Dietary fat and sports activity as determinants for age at menarche Am J Epidemiol 138 217 224
18. GA Colditz D Feskanich WY Chen 2003 Physical activity and risk of breast cancer in premenopausal women Br J Cancer 89 847 851
19. C Nagata N Takatsuka S Inaba 1998 Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women J Natl Cancer Inst 90 1830 1835
20. S Yamamoto T Sobue M Kobayashi 2003 Soy, isoflavones, and breast cancer risk in Japan J Natl Cancer Inst 95 906 913
21. SA Smith-Warner D Spiegelman SS Yaun 1998 Alcohol and breast cancer in women: a pooled analysis of cohort studies JAMA 279 535 540
22. SA Smith-Warner D Spiegelman HO Adami 2001 Types of dietary fat and breast cancer: a pooled analysis of cohort studies Int J Cancer 92 767 774
23. SA Missmer SA Smith-Warner D Spiegelman 2002 Meat and dairy food consumption and breast cancer: a pooled analysis of cohort studies Int J Epidemiol 31 78 85
24. TJ Key GE Fraser M Thorogood 1999 Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies Am J Clin Nutr 70 suppl 3 516S 524S
25. FJ Esteva AA Sahin M Cristofanilli 2002 Molecular prognostic factors for breast cancer metastasis and survival Semin Radiat Oncol 12 319 328
26. M Toi T Taniguchi T Ueno 1998 Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Clin Cancer Res 4 659 664
27. JS Ross JA Fletcher GP Linette 2003 The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy Oncologist 8 307 325
28. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene Science 235 177 182
29. H Tsuda K Iwaya T Fukutomi 1993 p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade Ipn J Cancer Res 84 394 401
30. H Schimmlepenning ET Eriksson L Pallis 1992 Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ Am J Clin Pathol 97 5 suppl 1 S48 S52
31. H Iwase Y Ando S Ichihara 2001 Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast Breast Cancer 8 98 104
32. H Schimmelpenning ET Eriksson UG Falkmer 1992 Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer Eur J Surg Oncol 18 530 537
33. M Venditti B Iwasiow FW Orr 2002 C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells Int J Cancer 99 35 42
34. AG Selim G El-Ayat M Naase 2002 C-myc oncoprotein expression and gene amplification in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast Breast 11 466 472
35. CM Schlotter U Vogt U Bosse 2003 C-myc, not Her2/neu, can predict recurrence and mortality of patients with node-negative breast cancer Breast Cancer Res 5 R30 R36
36. A Linjawi M Kontogiannea F Halwani 2004 Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer J Am Coll Surg 198 83 90
37. P Keohavong WM Gao HH Maby 2004 Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast Cancer Lett 212 121 130
38. EB Claus S Petruzella E Matloff 2005 Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ JAMA 293 964 969
39. B Shiptiz S Zimlichman R Zemer 1999 Telomerase activity in ductal carcinoma in situ of the breast Breast Cancer Res Treat 58 65 69
40. C Mueller U Riese H Kosmehl 2002 Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome Int J Oncol 20 385 390
41. M Swellam M Ismail S Eissa 2004 Emerging role of p53, bcl-2 and telomerase activity in Egyptian breast cancer patients IUBMB Life 56 483 490
42. T Morimoto M Sasa 1998 Current status of screening for breast cancer and tasks for introduction of mammographic screening in Japan Breast Cancer 25 227 234
43. N Ohuchi K Yoshida M Kimura 1993 Improved detection rate of early breast cancer in mass screening combined with mammography Jpn J Cancer Res 84 807 812
44. SR Benson J Blue K Judd 2004 Ultrasound is now better than mammography for the detection of invasive breast cancer Am J Surg 88 381 385
45. R Schulz-Wendtland K Bock U Airchinger 2005 Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics? (in German) Ultraschall Med 26 209 215
46. R Ohlinger GM Klein G Kohler 2004 Ultrasound of the breast: value of sonographic criteria for the differential diagnosis of solid lesions Ultraschall Med 25 48 53
47. D Watermann H Madjar W Sauerbrei 2004 Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival Oncol Rep 11 905 910
48. M Minato C Hirose M Sasa 2004 3-Dimensional computed tomography lymphography-guided identification of sentinel lymph nodes in breast cancer patients using subcutaneous injection of nonionic contrast medium: a clinical trial J Comput Assist Tomogr 28 46 51
49. G Trecate D Vergnaghi S Bergonzi 2003 Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: a preliminary experience Tumori 89 125 131
50. ES Hwang K Kinkel LJ Esserman 2003 Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity Ann Surg Oncol 10 381 388
51. PJ Lovrics V Chen G Coates 2004 A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer Ann Surg Oncol 11 846 853
52. E Barranger D Grahek M Antoine 2003 Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer Ann Surg Oncol 10 622 627
53. LE Philpotts NA Shaheen D Carter 1999 Comparison of rebiopsy rates after stereotactic core needle biopsy of the breast with 11-gauge vacuum suction probe versus 14-gauge needle and automatic gun Am J Roentgenol 172 683 687
54. U Kettritz K Rotter I Schreer 2004 Stereotatic vacuum-assisted breast biopsy in 2874 patients: a multicenter study Cancer (Phila) 100 245 251
55. K Spilsbury JB Semmens CM Saunders 2005 Subsequent surgery after initial breast conserving surgery: a population based study ANZ J Surg 75 260 264
56. BA Ward CF McKhann TS Ravikumar 1992 Ten-year follow-up of breast carcinoma in situ in Connecticut Arch Surg 127 1392 1395
57. NQ Mirza G Vlastos F Meric 2000 Ductal carcinoma-in-situ: long-term results of breast-conserving therapy Ann Surg Oncol 7 656 664
58. R Fonseca LC Hartmann IA Petersen 1997 Ductal carcinoma in situ of the breast Ann Intern Med 127 1013 1022
59. I Jatoi MA Proschan 2005 Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results Am J Clin Oncol 28 289 294
60. M Fatouros DH Roukos I Arampatzis 2005 Factors increasing local recurrence in breast-conserving surgery Expert Rev Anticancer 5 737 745
61. PT Truong CM Yong F Abnousi 2005 Lymphovascular invasion is associated with reduced locoregional control and survival in women with node-negative breast cancer treated with mastectomy and systemic therapy J Am Coll Surg 200 912 921
62. FA Vicini LL Kestin NS Goldstein 2004 Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis Int J Radiat Oncol Biol Phys 60 722 730
63. A Mannell 2005 Breast-conserving therapy in breast cancer patients: a 12-year experience S Afr J Surg 43 28 30
64. J Boyages G Delaney R Taylor 1999 Predictor of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis Cancer (Phila) 85 616 628
65. S Tangkaratt 2004 Mammographic findings in breast cancer patients, who were treated with breast conserving therapy J Med Assoc Thai 87 1439 1443
66. U Veronesi G Paganelli G Viale 2003 A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer N Engl J Med 349 546 553
67. R Gennari N Rotmensz E Perego 2004 Sentinel node biopsy in elderly breast cancer patients Surg Oncol 13 193 196
68. G Zavagno P Carcoforo Z Franchini 2005 Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients Eur J Surg Oncol 31 715 720
69. SE Singletary C Allred P Ashley 2002 Revision of the American Joint Committee on cancer staging system for breast cancer J Clin Oncol 20 3628 3636
70. K Dowlatshahi M Fan HC Snider 1997 Lymph node micrometastases from breast carcinoma: reviewing the dilemma Cancer (Phila) 80 1188 1197
71. U Veronesi G Paganelli G Viale 2003 A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer N Engl J Med 349 546 553
72. C Reynolds R Mick JH Donohue 1999 Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 17 1720 1726
73. KU Chu RR Turner NM Hansen 1999 Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 229 536 541
74. B Fisher J Dignam N Wolmark 1998 Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17 J Clin Oncol 16 441 452
75. Early breast cancer trialists' collaborative group 2000 Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group Lancet 355 1757 1770
76. GG Riberio B Magee R Swindell 1993 The Christie Hospital breast conservation trial: an update at 8 years from inception Clin Oncol (R Coll Radiol) 5 278 283
77. B Fisher C Redmond R Poisson 1989 Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer N Engl J Med 320 822 828
78. JA van Dongen H Bartelink IS Fentiman 1992 Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer, EORTC 10801 trial J Natl Cancer Inst Monogr 11 15 18
79. T Whelan R MacKenzie J Julian 2002 Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer J Natl Cancer Inst 94 1143 1150
80. CC Park M Mitsumori A Nixon 2000 Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence J Clin Oncol 18 1668 1675
81. MS Anscher P Jones LR Prosnitz 1993 Local failure and margin status in early-stage breast carcinoma treated with conservation surgery and radiation therapy Ann Surg 218 22 28
82. P Poortmans H Bartelink JC Horiot 2004 The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomized trial Randiother Oncol 72 25 33
83. H Bartelink JC Horiot P Poortmans 2001 Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation N Engl J Med 345 1378 1387
84. GD Leonard SM Swain 2004 Ductal carcinoma in situ, and challenges J Natl Cancer Inst 96 906 920
85. GF Schwartz LJ Solin IA Olivotto 2000 The consensus conference on the treatment of in situ ductal carcinoma of the breast, 22-25 April 1999 Breast 9 177 186
86. MS Mano A Awada 2004 Primary chemotherapy for breast cancer: the evidence and the future Ann Oncol 15 1161 1171
87. M Kaufmann G von Minckwitz R Smith 2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600 2608
88. A Goldhirsch WC Wood RD Gelber 2003 Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer J Clin Oncol 21 3357 3365
89. J Chang TJ Powles DC Allred 2000 Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients Clin Cancer Res 6 616 621
90. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 1717
91. B Fisher J Dignam J Bryant 2001 Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 684 690
92. Early Breast Cancer Trialists' Collaborative Group 1996 Ovarian ablation in early breast cancer: overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group Lancet 348 1189 1196
93. W Jonat M Kaufmann W Sauerbrei 2002 Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study J Clin Oncol 20 4628 4635
94. R Jakesz H Hausmaninger E Kubista 2002 Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer: Austrian Breast and Colorectal Cancer Study Group Trial 5 J Clin Oncol 20 4621 4627
95. NE Davidson A O'Neill A Vukov 2003 Chemohormonal therapy in premenopausal, node-positive, receptor-positive, breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188, INT-0101) Proc Am Soc Clin Oncol 22 15a
96. M Baum A Buzdar J Cuzick 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer (Phila) 98 1802 1810
97. N Wolmark J Wang E Mamounas 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102
98. JA van der Hage CJ Van de Velde JP Julien 2001 Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 4224 4237
99. HD Bear S Anderson A Brown 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174
100. R Jakesz W Jonat M Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462
101. RC Coombes E Hall LJ Gibson 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
102. PE Goss JN Ingle S Martino 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802
103. French Adjuvant Study Group 2001 Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 Randomized Trial J Clin Oncol 19 602 611
104. P Fumoleau P Kerbrat P Romestaing 2003 Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 Trial J Clin Oncol 21 298 305
105. IC Henderson DA Berry GD Demetri 2003 Improved outcomes from adding paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 15 976 983
106. EP Mamounas J Bryant B Lembersky 2005 Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28 J Clin Oncol 23 3686 3696
107. M Martin T Pienkowski J Mackey 2005 Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 2313
108. L Goldstein A O'Neill J Sparano 2003 E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high-risk node negative breast cancer Proc Am Soc Clin Oncol 22 512a
109. G Bonadonna P Valagussa C Brambilla 1998 Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 93 100
110. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
111. N Wolmark J Wang E Mamounas 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102
112. L Mauriac G MacGrogan A Avril 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 47 52
113. A Makris TJ Powles SE Ashley 1998 A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179 1184
114. V Valero 2002 Primary chemotherapy with docetaxel for the management of breast cancer Oncology (Huntingt) 16 35 43
115. B Fisher J Bryant N Wolmark 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685
116. IE Smith L Lipton 2001 Preoperative/neoadjuvant medical therapy for early breast cancer Lancet Oncol 2 561 570
117. Bear HD (2001) The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. In: 24th Annual San Antonio Breast Cancer Symposium, 10-13 Dec 2001, San Antonro, TX, abstract 5
118. IC Smith SD Heys AW Hutcheon 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 1466
119. DN Krag 1999 The sentinel node for staging breast cancer: current review Breast Cancer 25 233 236
120. U Veronesi V Galimberti S Zurrida 2001 Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer Eur J Cancer 37 454 458
121. TM Breslin L Cohen A Sahin 2000 Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer J Clin Oncol 18 3480 3486
122. KS Nason BO Anderson DR Byrd 2000 Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma Cancer (Phila) 89 2187 2194
123. TB Julian N Patel D Dusi 2001 Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer Am J Surg 182 407 410